Top

Published in:

01-10-2003 | Adis Drug Profile

Dutasteride

Authors: Hannah C. Evans, Karen L. Goa

Published in: Drugs & Aging | Issue 12/2003

Abstract

▴ Dutasteride, a potent inhibitor of type 1 and 2 5α-reductase, reduced dihydrotestosterone levels by >90% in 85% of patients following 1 years’ administration of oral dutasteride 0.5 mg/day.

▴ A combined analysis of three placebo-controlled clinical studies conducted in patients with benign prostatic hyperplasia (BPH) found sustained improvements in American Urological Association-Symptom Index scores and urinary flow rate and a 57% decrease in the risk of acute urinary retention throughout the 2-year treatment period (all p < 0.001 vs placebo).

▴ Total prostate and transition zone volume were also reduced (both p < 0.001), as was the risk of BPH-related surgery (by 48%).

▴ A nonblind extension study found that dutasteride maintains efficacy for up to 4 years. Dutasteride monotherapy maintained symptom relief following combination treatment with dutasteride and tamsulosin in all patients but those with severe symptoms.

▴ Dutasteride was generally well tolerated. Impotence, reduced libido, gynaecomastia and ejaculation disorder occurred significantly more often in dutasteride than placebo recipients, but incidence was generally low. With the exception of gynaecomastia, incidence consistently decreased over time.

Use of tradenames is for product identification purposes only and does not imply endorsement.

Frye S. Inhibitors of 5alpha-reductase. Curr Pharm Des 1996; 2: 59–84

Tammela T. Benign prostatic hyperplasia: practical treatment guidelines. Drugs Aging 1997; 10(5): 349–66PubMedCrossRef

Gisleskog PO, Hermann D, Hammarlund-Udenaes M, et al. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5alpha-reductase inhibitors GII98745 and finasteride. Clin Pharmacol Ther 1998; 64: 636–47PubMedCrossRef

Eri LM, Tveter KJ. Treatment of benign prostatic hyperplasia: a pharmacoeconomic perspective. Drugs Aging 1997; 10(2): 107–18PubMedCrossRef

Shirakawa T, Okada H, Fujisawa M, et al. Messenger RNA levels and enzyme activities of 5 alpha-reductase type 1 and 2 in the human benign prostatic hyperplasia tissues [abstract no. 461]. 32nd Annual Meeting of the International Continence Society; 2002 27–30 August; Heidelberg, Germany

Cooper KL, McKiernan JM, Kaplan SA. alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 1999; 57(1): 9–17PubMedCrossRef

Wilde MI, Goa KL. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs 1999; 57(4): 557–81PubMedCrossRef

GlaxoSmithKline. GlaxoSmithKline steps up efforts to recruit patients for clinical trial of dutasteride for prostate cancer [online]. Available from URL: http://www.gsk.com [Accessed 2003 Jul 2]

Tian G, Mook RA, Moss ML, et al. Mechanism of time-dependent inhibition of 5alpha-reductases by -4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry (Mosc) 1995; 34: 13453–9CrossRef

10.

Frye SV, Bramson HN, Hermann DJ, et al. Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. In: Borchardt RT, et al, editor. Integration of Pharmaceutical Discovery and Development: Case Studies. New York: Plenum Press, 1998; 11: 393–422CrossRef

11.

Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997; 282: 1496–502PubMed

12.

Hermann DJ, Wilson TH, Morrill BB. A 28-day evaluation of GI198745 (GG745), a potent dual 5-alpha reductase inhibitor, in BPH patients [abstract no. 1227]. J Urol 1997; 157 (4 Suppl.): 315

13.

Clark RV, Gabriel H, Hermann DJ, et al. Hormonal effects of GI198745, a novel 5 alpha reductase inhibitor [abstract no. P3-380]. 81st Annual Meeting of the Endocrine Society; 1999 12–15 June; San Diego, 520

14.

Clark RV, Hermann DJ, Gabriel H, et al. Almost complete suppression of dihydrotestosterone in men with benign prostatic hyperplasia by GI198745, a novel, dual 5alpha reductase inhibitor. North Carolina: GlaxoSmithKline (data on file)

15.

Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. ARIA 3001, ARIA 3002 and ARIA 3003 study investigators. Urology 2002 Sep; 60: 434–41PubMedCrossRef

16.

Clark RV, Huffman CS, Haberer LJ, et al. Marked suppression of dihydrotestosterone by dutasteride has no adverse effect on spermatogenesis in healthy men [abstract no. P2-673]. 84th Annual Meeting of the Endocrine Society; 2002 June 19–22; San Francisco, 478

17.

Clark RV, Matsumoto AM. Bone density, bone metabolism markers and lipid profiles in healthy men are unaffected by the novel dual 5A-reductase inhibitor dutasteride [abstract no. 1796]. J Urol 2003; 169 Suppl.: 479. Plus poster presented at the 98th Annual Meeting of the American Urological Association; 2003 April 26 to May 1; ChicagoCrossRef

18.

Critchley P, Brin S, Komas B, et al. Dutasteride: investigators brochure (US). GlaxoSmithKline, 2002

19.

GlaxoSmithKline. Safety and efficacy of Avodart for the treatment of benign prostatic hyperplasia: open-label results from the 4-year trial. GlaxoSmithKline, 2003; (data on file)

20.

Roehrborn CG, Andriole G, Nickel C, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on endocrine parameters [abstract no. 1049]. J Urol 2002 Apr; 167 (Suppl.): 266–7CrossRef

21.

Andriole G, Roehrborn CG, Nickel C, et al. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum total PSA, free PSA and the ratio of F/T PSA [abstract no. 844]. J Urol 2002 Apr; 167 Suppl.: 209–10

22.

Gisleskog PO, Hermann D, Hammarlund-Udenaes M, et al. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol 1999; 47: 53–8PubMedCrossRef

23.

GlaxoSmithKline UK. Avodart [online]. Available from URL: http://emc.vhn.net [Accessed 2003 Jun 10]

24.

GlaxoSmithKline. Avodart: Prescribing information. North Carolina: GlaxoSmithKline, 2002

25.

Clark RV, Haberer LJ, Horton JR, et al. No evidence of drug interactions between G1198745, a novel dual 5 alpha reductase inhibitor, and alpha 1 adrenergic antagonists. J Urol 2000 Apr; 163 Suppl.: 219–20CrossRef

26.

Clark RV, Hermann DJ, Gabriel H, et al. Effective suppression of dihydrotestosterone by GI198745, a novel, dual 5 alpha reductase inhibitor [abstract no. 1037]. J Urol 1999; 161(4): 268CrossRef

27.

Boyle P, Roehrborn C, Andriole G, et al. The impact of dutasteride, a novel 5-alpha reductase inhibitor, on the hallmarks of BPH progression and outcomes [abstract no. 418]. Eur Urol 2002; 41(Suppl. 1): 107. Plus poster presented at the 17th Congress of the European Association of Urology; 2002 Feb 23–26; Birmingham

28.

Boyle PP, Siami P, Wachs BH, et al. Effect of dutasteride on the risk of acute urinary retention and the need for surgical treatment. J Urol 2002 Apr; 167 Suppl.: 372

29.

Roehrborn C, Ramsdell J, Siami P, et al. Prostrate volume at baseline predicts the margin of therapeutic response with the 5-alpha-reductase inhibitor, dutasteride [abstract no. 1483]. J Urol 2002 Apr; 167 Suppl.: 373CrossRef

30.

Boyle P, Roehrborn C, Marks L, et al. Early use of dutasteride arrests prostate growth, improves clinical parameters and prevents complications in men with benign prostatic hyperplasia [abstract no. 1789]. J Urol 2003; 169 (4 Suppl.): 477

31.

Roehrborn CG, Andriole G, Nickel C, et al. Effect of dutasteride, a novel dual 5-alpha-reductase inhibitor, on BPH related signs and symptoms [abstract no. 1043]. J Urol 2002 Apr; 167 (4 Suppl.): 265

32.

Carson C, Harkaway R, Marks L, et al. Effect of maximal dihydrotestosterone suppression with dutasteride on sexual function and gynecomastia [abstract no. 1790]. J Urol 2003; 169 (4 Suppl.): 478. Plus poster presented at the 98th Annual Meeting of the American Urological Association; 2003 April 26 to May 1; Chicago

33.

O’Leary MP, Roehrborn C, Andriole G, et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 2003; 92(3): 262–6PubMedCrossRef

34.

Roehrborn CG, Boyle P, Nicket JC, et al. Dutasteride provides sustained and continued improvement in BPH-related symptoms over 4 years [abstract no. 1292]. J Urol 2003; 169 (4 Suppl.): 333. Plus oral presentation at the 98th Annual Meeting of the American Urological Association; 2003 April 26 to May 1; Chicago

35.

GlaxoSmithKline. New data evaluating four years of treatment with Avodart (dutasteride) support long-term efficacy and tolerability in men with BPH [online]. Available from URL: http://www.gsk.com [Accessed 2003 Apr 2]

36.

Barkin J, Guimaraes M, Do Castelo V, et al. Dutasteride provides sustained symptom relief following short term combination treatment with tamsulosin [abstract no. 1481]. J Urol 2002 Apr; 167 Suppl.: 372

37.

Poole RM. Dutasteride: rapid benefit in patients with BPH. Inpharma 2002 Mar 30; 1331: 9–10

38.

Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44(1): 82–8PubMedCrossRef

39.

GlaxoSmithKline. GlaxoSmithKline announces global launch of new treatment for benign prostatic hyperplasia [online]. Available from URL: http://www.gsk.com [Accessed 2003 Mar 20]

40.

EU market news. Inpharma 2002 Aug 10; 1350: 18

41.

GlaxoSmithKline. GlaxoSmithKline Receives European Approval for Avodart for Benign Prostatic Hyperplasia [online]. Available from URL: http://www.gsk.com [Accessed 2003 Sep 5]

42.

GlaxoSmithKline. FDA Approves Avodart, the First Dual-Acting 5 Alpha-Reductase Inhibitor for Benign Prostatic Hyperplasia (BPH) [online]. Available from URL: http://www.gsk.com [Accessed 2003 Sep 5]

Title: Dutasteride
Authors: Hannah C. Evans
Karen L. Goa
Publication date: 01-10-2003
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 12/2003
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200320120-00005

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2003

Dutasteride

Effects of Olanzapine on Lipid Abnormalities in Elderly Psychotic Patients

Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the Elderly

Diagnosis and Management of Panic Disorder in Older Patients

Brinzolamide

Dutasteride

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials